Also available in Persian — نسخه فارسی ✈️ Telegram EN فا
❓ Unknown

Brepocitinib yields improvements in cutaneous sarcoidosis

Just now November 19, 2026 1 min read 📰 Medical Xpress
📋 Key Takeaway

This article reports on a medical study showing that brepocitinib, a drug treatment, provides dose-dependent improvements for patients with cutaneous sarcoidosis. The study was presented at the American College of Rheumatology annual meeting in Orlando, Florida. This article contains no information related to Iran, Iranian politics, economics, military affairs, or international relations.

For patients with cutaneous sarcoidosis (CS), brepocitinib is associated with dose-dependent and clinically meaningful improvements, according to a study published online in JAMA Dermatology to coincide with the annual meeting of the American College of Rheumatology, held from Nov. 6 to 11 in Orlando, Florida.

🌐

Translated from the original and edited for English readers. View original source →

Translation confidence: 100%

📰 Related Coverage

⚖️ Independent Platform — Artesh.com is not affiliated with any government, military, or political organization. Editorial Policy →